Airsonett AB

📍 Ängelholm, Sweden👥 17 employees💰 Last funded Jul 2018
Medical Device🌐 airsonett.eu
Website LinkedIn
Airsonett is a Swedish medical device company that leads the way in the development of non-pharmaceutical treatment of allergic asthma and eczema. We do this by providing Airsonett AIR4, a safe and effective home treatment device that improve health-related quality of life. Main owners are Industrifonden, SEB Venture Capital, Magnus Lundberg and Fåhraeus Startup & Growth. Airsonett has an impressive patent portfolio and has invested heavily in clinical research and product development. Air4 creates a sleep zone that protects you from the exposure to allergens and particles that occur at night and we believe that everyone deserves to breathe perfectly clean air while they sleep. Air4 was initially created for people with severe atopic asthma who, in spite of taking asthma medication, still has poorly controlled asthma. Air4 is recommended by healthcare professionals as an effective at-home treatment for allergic asthma and other allergy induced diseases such as rhinitis and eczema. Using Air4 has no pharmacological side effects and is suitable for both adults and children.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Airsonett AB?
Airsonett AB has 1 investors on record on gritt.io.
When did Airsonett AB last raise funding?
The most recent investment in Airsonett AB recorded on gritt.io was in July 2018.
What industry is Airsonett AB in?
Airsonett AB operates in Medical Device. Find similar Medical Device investors on gritt.io.
Where is Airsonett AB based?
Airsonett AB is headquartered in Ängelholm, Sweden.